betazole dihydrochloride | 138-92-1

• 物质功能分类: 原料药 - 诊断用药 - 器官功能检查剂
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: betazole dihydrochloride
• 英文别名: Betazole hydrochloride；2-(1(2)H-pyrazol-3-yl)-ethylamine; dihydrochloride；2-(1(2)H-Pyrazol-3-yl)-aethylamin; Dihydrochlorid；1H-Pyrazole-3-ethanamine hydrochloride；2-(1H-pyrazol-5-yl)ethanamine;hydrochloride
• CAS: 138-92-1
• 化学式: C₅H₉N₃*2ClH
• 分子量: 184.068
• InChiKey: HLJRAERMLKNULP-UHFFFAOYSA-N

物化性质

• 熔点：
  224-226°
• 溶解度：
  DMSO：37 mg/mL (201.01 mM)；乙醇：18 mg/mL (97.79 mM)

计算性质

• 辛醇/水分配系数(LogP)：
  0.33
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54.7
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090
• 储存条件：
  2-8°C

制备方法与用途

生物活性方面，Betazole Dihydrochloride（Ametazole, 2-(3-吡唑基)乙胺）是一种组胺H2激动剂，在临床上用于检测胃分泌功能。

靶点
H2受体

体外研究表明，Betazole (Ametazole) dihydrochloride 是一种弱效的组胺激动剂，具有相对选择性地作用于H2受体，并且仅有微弱的H1活性。Betazole dihydrochloride 可以诱导胃抑制多肽（GIP）分泌。

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Double phase time-controlled release system
  申请人：Universiteit Leiden

  公开号：EP1095650A1

  公开（公告）日：2001-05-02

  The invention relates to a delivery system for active ingredients which comprises a swellable phase defining at least one void. In this void an active ingredient may be present. The active ingredient may be substantially enclosed by the swellable phase, optionally with a degradable layer present between the gel phase and the active ingredient. The invention further relates to a method for providing such delivery systems, a method for non-medical administration of active ingredients, as well as to the use of a swellable phase in controlled release systems.

  本发明涉及一种活性成分输送系统，该系统包括一个可膨胀相，该可膨胀相至少界定了一个空隙。在这个空隙中可以存在活性成分。活性成分可以基本上被可膨胀相包围，也可以在凝胶相和活性成分之间有一个可降解层。本发明还涉及提供这种给药系统的方法、活性成分的非医用给药方法以及可膨胀相在控释系统中的使用。
• METHOD FOR QUANTITATIVE MEASUREMENT OF GASTRIC ACIDITY USING 13C CARBONATE SALT
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：EP2618145A1

  公开（公告）日：2013-07-24

  The present invention provides a method for measuring the gastric acidity of a mammal using a 13C-labeled carbonate compound. Specifically, the present invention relates to a method for measuring the gastric acidity of a mammal including the following steps: (1) using, as a test sample, expired air of a mammalian subject excreted at any point in time within 30 minutes after oral administration of a predetermined amount of a 13C-labeled carbonate compound, measuring behavior of 13CO2 in the expired air; (2) comparing the behavior of 13CO2 (measured 13CO2 behavior) obtained in step (1) with the behavior of corresponding 13CO2 (reference 13CO2 behavior) that has been obtained beforehand in a control mammal; and (3) determining the gastric acidity of the mammalian subject based on a difference between the reference 13CO2 behavior and the measured 13CO2 behavior obtained above.

  本发明提供了一种使用 13C 标记的碳酸盐化合物测量哺乳动物胃酸度的方法。具体来说，本发明涉及一种测量哺乳动物胃酸度的方法，包括以下步骤： (1) 使用哺乳动物受试者在口服预定量的 13C 标记碳酸盐化合物后 30 分钟内的任意时间点排出的呼出空气作为测试样本，测量呼出空气中 13CO2 的行为； (2) 将步骤(1)中获得的 13CO2 行为（测量的 13CO2 行为）与事先在对照哺乳动物中获得的相应 13CO2 行为（参考 13CO2 行为）进行比较；以及 (3) 根据上述获得的参考 13CO2 行为和测量 13CO2 行为之间的差异确定哺乳动物的胃酸度。
• Methods and compositions for treating infection
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10004701B2

  公开（公告）日：2018-06-26

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。